Merck & Co. Adds Paul J. Diaz to Board

By Hao Liu • Tuesday, October 13 13:02 • Permanent Link

Merck & Co. said Paul J. Diaz will join its board of directors effective Nov. 1, 2026, expanding the board to 14 members from 13.

Diaz, managing partner at Cressey & Company, will stand for election by shareholders in May 2027. He previously served as president and chief executive officer of Myriad Genetics and before that led Kindred Healthcare as president and chief executive officer. He also serves on the board of Centene Corporation.

Merck said Diaz brings healthcare industry leadership and business experience to the board. The company did not announce any other changes to its directors. The market has reacted to these announcements by moving the company's shares -0.1% to a price of $145.45. For the full picture, make sure to review Merck &'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.